Policlinico Casilino   Report issue

Academic/Hospital Phase 3 Phase 4
Founded: Rome Italy (1995)

Organization Overview

First Clinical Trial
2013
NCT01657136
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Policlinico Casilino | Policlinico Casilino ASL RMB

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Heart Failure (Phase 4)

Hypercholesterolemia (Phase 4)

Kidney Diseases (Phase 4)

Renal Insufficiency, Chronic (Phase 4)

Tachycardia (Phase 3)

Tachycardia, Sinus (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 8